SCHEMBL6972578

SCHEMBL6972578

CCCCc1ncc(COC(C)=O)n1Cc1ccccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7099500 0.85 — —
SCHEMBL7269745 0.84 — —
SCHEMBL9474239 0.84 — —
SCHEMBL9472975 0.84 — —
SCHEMBL8954104 0.83 — —
SCHEMBL6968202 0.83 — —
SCHEMBL9202734 0.83 — —
Hydrochloric Acid SCHEMBL9473508 0.83 — —
SCHEMBL8954232 0.83 — —
SCHEMBL9474682 0.82 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030187044-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-10-02 — — US disclosed
EP-0955294-B1 Imidazolyl-alkenoic acid SMITHKLINE BEECHAM CORP (US) 2003-09-24 — — EP disclosed
US-20030166700-A1 Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression SMITHKLINE BEECHAM P.L.C. 2003-09-04 — — US disclosed
US-20030096851-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-05-22 — — US disclosed
US-20030069293-A1 Medicament SMITHKLINE BEECHAM PLC 2003-04-10 — — US disclosed
US-20030050285-A1 Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke SMITHKLINE BEECHAM P.L.C. 2003-03-13 — — US disclosed
US-20030004201-A1 Medicament SMITHKLINE BEECHAM P.L.C. 2003-01-02 — — US disclosed
US-20020160985-A1 Medicament SMITHKLINE BEECHAM PLC 2002-10-31 — — US disclosed
EP-0641203-B1 PHARMACEUTICAL COMPOSITIONS OF AN IMIDAZOLYL-AKENOIC ACID SALT AND THEIR USE AS ANGIOTENSIN II ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-16 — — EP disclosed
US-20020132840-A1 Treating angina in a mammal by administering an angiotensin II receptor antagonist. SMITHKLINE BEECHAM P.1.C. 2002-09-19 — — US disclosed
WO-1992010186-A1 USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010097-A1 ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS SMITHKLINE BEECHAM CORPORATION (US) 1992-06-25 — — WO disclosed
WO-1992010185-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010184-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010183-A1 USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF DIABETIC RETINOPATHY SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010180-A1 USE OF ANGIOTENSIN II ANTAGONIST IN THE TREATMENT OF INFARCTION SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992010187-A1 USE OF ANGIOTENSIN II ANTAGONISTS IN THE TREATMENT OF ANGINA PECTORIS SMITHKLINE BEECHAM PLC (GB) 1992-06-25 — — WO disclosed
WO-1992002510-A1 SUBSTITUTED [1H-IMIDAZOL-5-YL]ALKANOIC ACIDS SMITHKLINE BEECHAM CORPORATION (US) 1992-02-20 — — WO disclosed
WO-1992000068-A1 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORPORATION (US) 1992-01-09 — — WO disclosed
EP-0437103-A2 Substituted 5-(alkyl)carboxamide imidazoles SMITHKLINE BEECHAM CORPORATION (US) 1991-07-17 — — EP disclosed
Send feedback